HPM Partners LLC raised its holdings in shares of Express Scripts Holding Co (NASDAQ:ESRX) by 9.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,828 shares of the company’s stock after purchasing an additional 1,795 shares during the quarter. HPM Partners LLC’s holdings in Express Scripts were worth $1,608,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in the business. Sumitomo Life Insurance Co. lifted its holdings in shares of Express Scripts by 4.5% during the second quarter. Sumitomo Life Insurance Co. now owns 15,313 shares of the company’s stock worth $1,182,000 after buying an additional 657 shares in the last quarter. Gibraltar Capital Management Inc. lifted its holdings in shares of Express Scripts by 1.1% during the second quarter. Gibraltar Capital Management Inc. now owns 68,278 shares of the company’s stock worth $5,272,000 after buying an additional 750 shares in the last quarter. Pitcairn Co. lifted its holdings in shares of Express Scripts by 6.0% during the first quarter. Pitcairn Co. now owns 13,465 shares of the company’s stock worth $930,000 after buying an additional 761 shares in the last quarter. Hancock Holding Co. lifted its holdings in shares of Express Scripts by 3.4% during the first quarter. Hancock Holding Co. now owns 23,052 shares of the company’s stock worth $1,592,000 after buying an additional 764 shares in the last quarter. Finally, Pinnacle Financial Partners Inc. lifted its holdings in shares of Express Scripts by 9.9% during the second quarter. Pinnacle Financial Partners Inc. now owns 8,600 shares of the company’s stock worth $663,000 after buying an additional 773 shares in the last quarter. 84.73% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ ESRX opened at $91.82 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.59 and a debt-to-equity ratio of 0.69. Express Scripts Holding Co has a 52 week low of $55.80 and a 52 week high of $91.88. The firm has a market capitalization of $50.57 billion, a P/E ratio of 12.93, a P/E/G ratio of 1.13 and a beta of 1.00.
In related news, insider Christine Houston sold 12,898 shares of the firm’s stock in a transaction on Friday, August 10th. The stock was sold at an average price of $85.00, for a total value of $1,096,330.00. Following the transaction, the insider now owns 110,908 shares in the company, valued at $9,427,180. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.79% of the stock is currently owned by company insiders.
A number of research firms have recently weighed in on ESRX. Robert W. Baird downgraded Express Scripts from an “outperform” rating to a “neutral” rating and set a $81.00 target price for the company. in a report on Friday, July 20th. BidaskClub raised Express Scripts from a “hold” rating to a “buy” rating in a report on Wednesday, June 13th. William Blair raised Express Scripts from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 1st. Zacks Investment Research downgraded Express Scripts from a “hold” rating to a “sell” rating in a report on Monday, July 23rd. Finally, Royal Bank of Canada lifted their target price on Express Scripts to $94.00 and gave the stock an “outperform” rating in a report on Monday, August 27th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $85.58.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Featured Article: Using the New Google Finance Tool
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.